Bhopal-based molecular diagnostics kit maker (TRUPCR qPCR, TRURAPID lateral-flow, TRUNGS NGS assays) with a legacy agrochemicals division, plus UK (TRUPCR Europe) and Belgium (Coris BioConcept) subsidiaries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 25 | 125 | 146 | 185 | 214 | 260 | 290 | 316 |
| Borrowings | 4 | 2 | 3 | 2 | 1 | 0 | 0 | 3 |
| Other Liabilities | 9 | 59 | 37 | 19 | 24 | 27 | 42 | 51 |
| Total Liabilities | 45 | 194 | 192 | 214 | 248 | 296 | 341 | 378 |
| AssetsFixed Assets | 4 | 5 | 7 | 8 | 7 | 7 | 17 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 59 | 93 | 92 | 117 | 156 | 160 | 158 |
| Other Assets | 40 | 130 | 93 | 114 | 123 | 132 | 163 | 193 |
| Total Assets | 45 | 194 | 192 | 214 | 248 | 296 | 341 | 378 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 4 | 7 | 98 | 37 | 20 | 27 | 43 | 52 |
| Cash from Investing | -1 | -1 | -70 | -28 | 15 | -20 | -33 | -24 |
| Cash from Financing | -1 | 1 | -2 | -15 | -5 | -4 | -3 | -1 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 3 | 6 | 96 | 35 | 18 | 26 | 42 | 27 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (21.3×) and current (19.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 26.5% growth and a 20× exit, ₹1197 only delivers your return if you pay ₹1,813. The price is currently baking in 17% growth.
EPS grows 26.5%/yr for 5 years, then fades to 6% over 2, exits at 20×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 26.5% | 76.42 |
| FY28 | 26.5% | 96.67 |
| FY29 | 26.5% | 122.29 |
| FY30 | 26.5% | 154.69 |
| FY31 | 26.5% | 195.69 |
| FY32 | 16.3% ·fade | 227.49 |
| FY33 | 6.0% ·fade | 241.14 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.